Connectors for bifurcated stent

Abstract
A stent assembly comprises a second stent body and a substantially tubular first stent body defining a first lumen and containing a side branch opening. In an undeployed state, the second stent body is at least partially comprised of rings having peaks and valleys at least some of the valleys of adjacent rings being interconnected by bridges. In an expanded state, the rings of the second stent body define a second lumen opening in fluid communication with the first lumen. The second lumen has superior body vessel coverage and is flexible enough to form an oblique angle relative to the longitudinal axis of the first stent body.
Description
CROSS-REFERENCE TO RELATED APPLICATIONS

Not Applicable


STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH

Not Applicable


FIELD OF THE INVENTION

In some embodiments this invention relates to implantable medical devices, their manufacture, and methods of use. Some embodiments are directed to delivery systems, such as catheter systems of all types, which are utilized in the delivery of such devices.


BACKGROUND OF THE INVENTION

Stents, grafts, stent-grafts, vena cava filters, expandable frameworks, and similar implantable medical devices, collectively referred to hereinafter as stents, are radially expandable endoprostheses which are typically intravascular implants capable of being implanted transluminally and enlarged radially after being introduced percutaneously. Stents may be implanted in a variety of body lumens or vessels such as within the vascular system, urinary tracts, bile ducts, fallopian tubes, coronary vessels, secondary vessels, etc. Stents may be implanted to prevent restenosis following angioplasty in the vascular system. They may be self-expanding, expanded by an internal radial force, such as when mounted on a balloon, or a combination of self-expanding and balloon expandable (hybrid expandable).


Stents may be created by methods including cutting or etching a design from a tubular stock, from a flat sheet which is cut or etched and which is subsequently rolled or from one or more interwoven wires or braids.


Within the vasculature, it is not uncommon for stenoses to form at a vessel bifurcation. A bifurcation is an area of the vasculature or other portion of the body where a first (or parent) vessel is bifurcated into two or more branch vessels. Where a stenotic lesion or lesions form at such a bifurcation, the lesion(s) can affect only one of the vessels (i.e., either of the branch vessels or the parent vessel) two of the vessels, or all three vessels. Many prior art stents however are not wholly satisfactory for use where the site of desired application of the stent is juxtaposed or extends across a bifurcation in an artery or vein such, for example, as the bifurcation in the mammalian aortic artery into the common iliac arteries.


The art referred to and/or described above is not intended to constitute an admission that any patent, publication or other information referred to herein is “prior art” with respect to this invention. In addition, this section should not be construed to mean that a search has been made or that no other pertinent information as defined in 37 C.F.R. §1.56(a) exists.


All US patents and applications and all other published documents mentioned anywhere in this application are incorporated herein by reference in their entirety.


Without limiting the scope of the invention a brief summary of some of the claimed embodiments of the invention is set forth below. Additional details of the summarized embodiments of the invention and/or additional embodiments of the invention may be found in the Detailed Description of the Invention below.


A brief abstract of the technical disclosure in the specification is provided as well only for the purposes of complying with 37 C.F.R. 1.72. The abstract is not intended to be used for interpreting the scope of the claims.


BRIEF SUMMARY OF THE INVENTION

At least one possible embodiment is directed to a stent comprising a tubular body having a sidewall with a plurality of openings therethrough. A portion of the sidewall has a plurality of rings which are concentric and interconnected, including a first ring and a second ring. Both rings have peaks and valleys. A first connector extending from a valley of the first ring to the valley of the second ring connects the rings.


At least one possible embodiment is directed to a stent wherein the first and second rings are connected by a plurality of connectors, the connectors extending from one valleys of the first ring to valleys of the second ring.


At least one possible embodiment is directed to a stent wherein each of the concentric rings has a plurality of peaks and valleys, each two adjacent concentric rings connected by at least one connector which extends from a valley of one of the two adjacent rings to a valley of the other of the two adjacent rings.


At least one possible embodiment is directed to a stent wherein each of the concentric rings has a plurality of peaks and valleys, each two adjacent concentric rings connected by a plurality of connectors which extend from valleys of one of the two adjacent rings to valleys of the other of the two adjacent rings.


At least one possible embodiment is directed to a stent in which the peaks and valleys of the concentric rings are out of phase with each other.


At least one possible embodiment is directed to a stent in which at least one connector is more rigid than at least one ring.


At least one possible embodiment is directed to a stent in which at least one ring is more rigid than at least one connector.


At least one possible embodiment is directed to a stent in which at least one connector and at least one concentric ring are constructed out of different materials.


At least one possible embodiment is directed to a stent in which the connectors are connected to every other valley of at least one ring.


At least one possible embodiment is directed to a bifurcated stent having a tubular sidewall, the sidewall including an expandable sidebranch portion, the expandable sidebranch portion having a plurality of rings which are concentric and interconnected, including a first ring and a second ring. Both rings have peaks and valleys. A first connector extending from a valley of the first ring to the valley of the second ring connects the rings.


At least one possible embodiment is directed to a bifurcated stent in which the first and second rings are connected by a plurality of connectors, the connectors extending from one valleys of the first ring to valleys of the second ring.


At least one possible embodiment is directed to a bifurcated stent in which the first ring defines the outermost end of the expandable sidebranch portion.


At least one possible embodiment is directed to a bifurcated stent in which the peaks and valleys of the concentric rings are out of phase with each other.


At least one possible embodiment is directed to a bifurcated stent in which at least one connector is more rigid than at least one ring.


At least one possible embodiment is directed to a bifurcated stent in which at least one ring is more rigid than at least one connector.


At least one possible embodiment is directed to a bifurcated stent in which at least one connector and at least one concentric ring are constructed out of different materials.


At least one possible embodiment is directed to a bifurcated stent in which the connectors are connected to every other valley of at least one ring.


At least one possible embodiment is directed to a bifurcated stent being expandable from an unexpanded state to an expanded state, wherein in the unexpanded state the stent has a diameter less than that of the diameter in the expanded state. The bifurcated stent comprises: a substantially tubular primary body defining a primary circumferential plane, a primary outer surface, a primary lumen and having a primary longitudinal axis extending therethrough and has a side opening and a side branch assembly engaged to the primary body opposite the side opening. The side branch assembly comprises at least two ring members. In the unexpanded state the at least two ring members are positioned substantially within the primary circumferential plane. In the expanded state at least one ring member is positioned external to the first circumferential plane and the at least two ring members define a secondary circumferential plane, a secondary lumen, and having a secondary longitudinal axis extending therethrough. The secondary lumen is in fluid communication with the primary lumen and the secondary longitudinal axis forms an oblique angle with the primary longitudinal axis. The ring members are interconnected by connectors and comprising a plurality of peaks and valleys, at least one of the connectors connecting the valley of one ring member to the valley of another ring member.


At least one possible embodiment is directed to a bifurcated stent in which one half of all the valleys of at least one ring members are connected to one half of the ring members of at least one other ring member.


These and other embodiments which characterize the invention are pointed out with particularity in the claims annexed hereto and forming a part hereof.


However, for further understanding of the invention, its advantages and objectives obtained by its use, reference can be made to the drawings which form a further part hereof and the accompanying descriptive matter, in which there is illustrated and described embodiments of the invention.





BRIEF DESCRIPTION OF THE SEVERAL VIEWS OF THE DRAWING(S)

A detailed description of the invention is hereafter described with specific reference being made to the drawings.



FIG. 1 is a view of an unexpanded bifurcated stent having a side branch assembly with bridged rings.



FIG. 2 is a view of an expanded bifurcated stent having a side branch assembly with bridged rings.



FIG. 3 is a view of a bifurcated stent with long bridges.



FIG. 4 is a detailed view of the side branch assembly of a bifurcated stent assembly made of rings connected by valley-valley bridges.





DETAILED DESCRIPTION OF THE INVENTION

While this invention may be embodied in many different forms, there are described in detail herein specific embodiments of the invention. This description is an exemplification of the principles of the invention and is not intended to limit the invention to the particular embodiments illustrated.


For the purposes of this disclosure, like reference numerals in the figures shall refer to like features unless otherwise indicated.


Depicted in the figures are various aspects of the invention. Elements depicted in one figure may be combined with, and/or substituted for, elements depicted in another figure as desired.


Referring now to FIG. 1 there is shown a tubular body which is an unexpanded bifurcated stent 1 extending along a first longitudinal axis 16 having a first stent body 10 with at least one side opening 18 along its sidewall. Although this illustration shows a first stent body 10 having a plurality of struts 5 forming columns 7, the invention encompasses all stent structures currently known in the art. In the expanded state, the first stent body will define a first fluid lumen 14.


First stent body 10 can be constructed from any suitable biocompatible material including but not limited to polymers, stainless steel, platinum, gold, cobalt, chromium, niobium etc. It can also be constructed out of one or more combinations and/or alloys of these materials.


An improved side branch assembly 30 is connected to first stent body 10 adjacent to the side opening 18. As illustrated in FIG. 2, when the stent is in its expanded state, the side branch assembly 30 will define a second fluid lumen 34 in fluid communication with the first fluid lumen 14 with a second longitudinal axis 36 extending therethrough. The second longitudinal axis 36 can be oriented at an angle 90 with respect to the longitudinal axis 16 of the first stent body 10. The region of the side branch assembly 30 that is generally connected to the first stent body 10 by connectors 39 in the expanded state comprises an end of the second fluid lumen 34 and is referred to as the “ostium” 38. The opposite end of the expanded second fluid lumen 34 is the outermost end 40. For purposes of this application and in particular when describing the drawings, when discussing a set of items, the item described as “ostial” is the item of the set closest to the ostium and the item described as “outermost” is the item of the set furthest away from the ostium.


The side branch assembly 30 of FIGS. 1 and 2 comprises a plurality of rings or ring members 33. As illustrated in FIG. 1, when the stent 1 is in an unexpanded state, each ring is positioned in a nested arrangement. For purposes of this application the term “nested” includes but is not limited to concentric, stacked, overlapping, and adjacent ring arrangements. The rings may surround a center point 31. As the stent 1 expands, at least one ring 33 is either self expanded or pushed by an expansion mechanism such as a balloon away from the ostium 38 and into the body vessel branch. The extension of the rings 33 forms a generally serial configuration and defines at least a portion of a generally tubular secondary fluid lumen 34 in fluid communication with the first fluid lumen 14. At least a portion of the secondary fluid lumen 34 is located between an ostial ring closest to the ostium 38 and an outermost ring 40. Some or all of the rings can be connected to each other by ring-ring connectors 37 or to the first stent body by ring-stent connectors 39. In one possible embodiment, each ring is connected to an adjacent ring by a connector 37 and only the ostial ring is connected to the first stent body by a connector 39.


Referring now to FIG. 3 there is shown a detailed illustration of a side branch assembly designed according to the current state of the art. It features rings 33, connectors 67, and connectors 39. The rings are all in phase with each other and the inter ring connectors 67 can be characterized as connecting the peak 50 of one ring to the peak 50 of another. This design also features connectors 67 and connectors 39 extending into all of the rings and connecting with the first stent body 10.


For purposes of this application, the term “in phase” means the rings 33 are generally concentric and project towards and away from the center point 31 at relatively similar rotational positions along their perimeters. For example, peaks 50 of one ring 33 are aligned with peaks 50 of another ring 33 in a sidebranch radial direction In contrast, “out of phase” means the rings 33 are not in similar rotational positions. When rings are in phase, a connector 67 oriented along a vector generally directed towards the center point 31 is typically a peak-peak or valley-valley connection. Conversely, a connector 37 see FIG. 4) according to embodiments of the present invention connecting two out of phase rings can be a peak-valley connection. FIG. 3 features peak-peak connectors 67 and FIG. 4 features peak-valley connectors 37.


Referring now to FIG. 4 there is shown a detailed illustration of an embodiment for the improved side branch assembly 30. At least two of the rings 33 comprise a plurality of peaks 50 and valleys 52 connected by struts 54 extending along the rings' 33 perimeter. The rings 33 themselves are interconnected by at least one connector 37 connecting a peak 50 of one ring 33 to a valley 52 of an adjacent ring 33. By using peak-valley connectors 37 to link the rings 33, the extent of coverage the expanded side branch assembly provides to the body vessel increases. In addition, by replacing long connectors 67 of FIG. 3 with a multiplicity of shorter connectors 37 more widely distributed between different regions of the rings 33, the expanded side branch assembly 30 of FIG. 4 has greater flexibility than the side branch assembly of FIG. 3.



FIG. 4 is a representational illustration of the improved side branch assembly 30, but there are number of alternative designs that this invention encompasses. FIG. 4 contains three rings 33 a first and a third in phase with each other and a second exactly out of phase with the first and the third. The rings need not be exactly in phase with each other. In addition, the figure shows rings with eight peaks, eight valleys, four ring-ring connectors, and four ring-stent connectors and that every other valley is interconnected. Any number of connectors can be used. The figure also shows the connectors connecting a given ring to a less ostial ring are located on the valley immediately counterclockwise to a valley with an ostial connector or bridge. This relative positioning of the bridges and/or connectors is not an essential feature of the invention. This invention at a minimum encompasses a side branch assembly 30 with at least two rings each having at least two valleys, one connector and one bridge connecting the two valleys.


Although the figure shows a single side branch opening and a singe side branch assembly, there can be multiple side branch openings and side branch assemblies.


The sizes of the side branches can vary as well having larger, smaller or the same area, end-on-end length, or circumference in the extended or unextended states. Multiple side branch openings can be positioned anywhere along the length of the first stent body 1 and can be coaxially positioned relative to one another.


In embodiments wherein the side branch assembly 30 is configured to be self expanding, the stent 1 can be designed such that first body stent struts 5 can partially cover and restrain the side branch assembly 30 in the unexpanded state. In such an embodiment, as the first stent body 10 expands (whether through balloon expansion or by self expansion) its movement will move the covering struts 5 from the side branch assembly 30, allowing the side branch assembly to self-expand. In the case of a balloon expandable side branch assembly 30, the stent 1 can also be designed so that the unexpanded first stent struts 5 can at least partially cover the side branch assembly 30 and can be moved away as the first stent body 10 expands. As mentioned before, this inventive concept is not limited to stents comprising struts and can be accomplished with any stent structure in which in the unexpanded state the stent has a structural component adjacent to the structural components of the side branch assembly and in the expanded state the structural components are moved away from the side branch assembly.


One way to vary the degree of structural strength or flexibility that the expanded side branch assembly 30 will have is by constructing various parts of the side branch assembly 30 out of materials with different properties. For example, the connectors 39, connectors 37, and rings 33 can each be constructed out of different materials with differing structural strength or flexibility. In addition, each ring 33, each connector 37, or each connector 39, can be made out of similarly different materials.


The inventive stents may be made from any suitable biocompatible materials including one or more polymers, one or more metals or combinations of polymer(s) and metal(s). Examples of suitable materials include biodegradable materials that are also biocompatible. By biodegradable is meant that a material will undergo breakdown or decomposition into harmless compounds as part of a normal biological process. Suitable biodegradable materials include polylactic acid, polyglycolic acid (PGA), collagen or other connective proteins or natural materials, polycaprolactone, hylauric acid, adhesive proteins, co-polymers of these materials as well as composites and combinations thereof and combinations of other biodegradable polymers. Other polymers that may be used include polyester and polycarbonate copolymers. Examples of suitable metals include, but are not limited to, stainless steel, titanium, tantalum, platinum, tungsten, gold and alloys of any of the above-mentioned metals. Examples of suitable alloys include platinum-iridium alloys, niobium alloys, cobalt-chromium alloys including Elgiloy and Phynox, MP35N alloy and nickel-titanium alloys, for example, Nitinol.


The inventive stents may be made of shape memory materials such as superelastic Nitinol or spring steel, or may be made of materials which are plastically deformable. In the case of shape memory materials, the stent may be provided with a memorized shape and then deformed to a reduced diameter shape. The stent may restore itself to its memorized shape upon or after being heated to a transition temperature and having any restraints removed therefrom.


The inventive stents may be created by methods including cutting or etching a design from a tubular stock, from a flat sheet which is cut or etched and which is subsequently rolled or from one or more interwoven wires or braids. Any other suitable technique which is known in the art or which is subsequently developed may also be used to manufacture the inventive stents disclosed herein.


In some embodiments the stent, the delivery system or other portion of the assembly may include one or more areas, bands, coatings, members, etc. that is (are) detectable by imaging modalities such as X-Ray, MRI, ultrasound, etc. In some embodiments at least a portion of the stent and/or adjacent assembly is at least partially radiopaque.


In some embodiments the at least a portion of the stent is configured to include one or more mechanisms for the delivery of a therapeutic agent. Often the agent will be in the form of a coating or other layer (or layers) of material placed on a surface region of the stent, which is adapted to be released at the site of the stent's implantation or areas adjacent thereto.


A therapeutic agent may be a drug or other pharmaceutical product such as non-genetic agents, genetic agents, cellular material, etc. Some examples of suitable non-genetic therapeutic agents include but are not limited to: anti-thrombogenic agents such as heparin, heparin derivatives, vascular cell growth promoters, growth factor inhibitors, Paclitaxel, etc. Where an agent includes a genetic therapeutic agent, such a genetic agent may include but is not limited to: DNA, RNA and their respective derivatives and/or components; hedgehog proteins, etc. Where a therapeutic agent includes cellular material, the cellular material may include but is not limited to: cells of human origin and/or non-human origin as well as their respective components and/or derivatives thereof. Where the therapeutic agent includes a polymer agent, the polymer agent may be a polystyrene-polyisobutylene-polystyrene triblock copolymer (SIBS), polyethylene oxide, silicone rubber and/or any other suitable substrate.


The above disclosure is intended to be illustrative and not exhaustive. This description will suggest many variations and alternatives to one of ordinary skill in this art. The various elements shown in the individual figures and described above may be combined or modified for combination as desired. All these alternatives and variations are intended to be included within the scope of the claims where the term “comprising” means “including, but not limited to”.


Further, the particular features presented in the dependent claims can be combined with each other in other manners within the scope of the invention such that the invention should be recognized as also specifically directed to other embodiments having any other possible combination of the features of the dependent claims. For instance, for purposes of claim publication, any dependent claim which follows should be taken as alternatively written in a multiple dependent form from all prior claims which possess all antecedents referenced in such dependent claim if such multiple dependent format is an accepted format within the jurisdiction (e.g. each claim depending directly from claim 1 should be alternatively taken as depending from all previous claims). In jurisdictions where multiple dependent claim formats are restricted, the following dependent claims should each be also taken as alternatively written in each singly dependent claim format which creates a dependency from a prior antecedent-possessing claim other than the specific claim listed in such dependent claim below.


This completes the description of the invention. Those skilled in the art may recognize other equivalents to the specific embodiment described herein which equivalents are intended to be encompassed by the claims attached hereto.

Claims
  • 1. A stent comprising a tubular body having a sidewall with a plurality of openings therethrough, a portion of the sidewall having a plurality of rings which are concentric about a centerpoint located on said sidewall, including a first ring and a second ring, the first ring comprising alternating peaks and valleys connected by struts and the second ring comprising alternating peaks and valleys connected by struts, the peaks of a ring located closer to the centerpoint than the valleys of the ring, the first ring having the same number of peaks and valleys as the second ring, the struts of the second ring being longer than the struts of the first ring, and a connector extending from a peak of the first ring to a valley of the second ring, said connector being straight along its length.
  • 2. The stent of claim 1 wherein the first and second rings are connected by a plurality of connectors, each connector extending from a peak of the first ring to a valley of the second ring.
  • 3. The stent of claim 2 wherein each of the connectors extend in a side branch radial direction.
  • 4. The stent of claim 1 further comprising a third ring concentric with said second ring, said third ring comprising alternating peaks and valleys connected by struts, the second ring having the same number of peaks and valleys as the third ring, the struts of the third ring being longer than the struts of the second ring, and a connector extending between a peak of the second ring and a valley of the third ring.
  • 5. The stent of claim 4 wherein each peak of said first ring is aligned with a peak of said third ring in a side branch radial direction.
  • 6. The stent of claim 4 wherein each valley of said second ring is aligned with a peak of said third ring in a side branch radial direction.
  • 7. The stent of claim 1 wherein each peak of said first ring is aligned with a valley of said second ring in a side branch radial direction.
  • 8. The stent of claim 1 in which at least one connector and at least one concentric ring are constructed out of different materials.
  • 9. The stent of claim 1 wherein a connector is connected to every other peak of said first ring.
  • 10. A bifurcated stent having a tubular sidewall, the sidewall including an expandable sidebranch portion, the expandable sidebranch portion comprising a plurality of rings which are concentric about a centerpoint, including a first ring and a second ring, the first ring comprising alternating peaks and valleys connected by struts and the second ring comprising alternating peaks and valleys connected by struts, the peaks of a ring located closer to the centerpoint than the valleys of the ring, the first ring having the same number of peaks and valleys as the second ring, each peak of the first ring aligned with a valley of the second ring in a sidebranch radial direction, the struts of the second ring being longer than the struts of the first ring, and a connector extending from a peak of the first ring to a valley of the second ring, said connector oriented in a sidebranch radial direction.
  • 11. The bifurcated stent of claim 10 comprising a plurality of connectors, each connector extending from a peak of the first ring to a valley of the second ring.
  • 12. The bifurcated stent of claim 10 in which the first ring defines the outermost end of the expandable sidebranch portion when the sidebranch portion is outwardly deployed.
  • 13. The bifurcated stent of claim 10 in which each valley of the first ring is aligned with a peak of the second ring in a sidebranch radial direction.
  • 14. The bifurcated stent of claim 10 in which at least one connector is more rigid than at least one ring.
  • 15. The bifurcated stent of claim 10 in which at least one ring is more rigid than at least one connector.
  • 16. The bifurcated stent of claim 10 in which at least one connector and at least one concentric ring are constructed out of different materials.
  • 17. The bifurcated stent of claim 10 wherein a connector is connected to every other valley of said second ring.
  • 18. A bifurcated stent being expandable from an unexpanded state to an expanded state, wherein in the unexpanded state the stent has a diameter less than that of the diameter in the expanded state, the bifurcated stent comprising: a substantially tubular primary body defining a sidewall, a primary lumen and having a primary longitudinal axis extending therethrough, said sidewall having a side opening;a side branch assembly engaged to the primary body and located within the side opening, the side branch assembly comprising at least two ring members, in the unexpanded state the at least two ring members being positioned substantially within the sidewall, in the expanded state at least one ring member being positioned external to the sidewall, and the at least two ring members defining a secondary lumen having a secondary longitudinal axis extending therethrough, the secondary lumen being in fluid communication with the primary lumen, the secondary longitudinal axis forming an angle with the primary longitudinal axis;the ring members each comprising a plurality of alternating peaks and valleys connected by struts, the peaks of a ring located closer to a center of the side branch assembly than the valleys of the ring, the first ring having the same number of peaks and valleys as the second ring, the struts of the second ring being longer than the struts of the first ring, the ring members connected by at least one connector extending from a peak of one ring member to the valley of another ring member in a side branch radial direction.
  • 19. The bifurcated stent of claim 18 comprising a plurality of connectors, each connector extending from a peak of the first ring member to a valley of the second ring member, wherein half of the valleys of the second ring member are connected to a connector.
US Referenced Citations (319)
Number Name Date Kind
1596754 Moschelle Aug 1926 A
1861769 Wappler Jun 1932 A
2845959 Sidebotham Aug 1958 A
3872893 Roberts Mar 1975 A
4309994 Grunwald Jan 1982 A
4410476 Redding et al. Oct 1983 A
4413989 Schjeldahl et al. Nov 1983 A
4421810 Rasmussen Dec 1983 A
4454887 Kruger Jun 1984 A
4552554 Gould et al. Nov 1985 A
4681570 Dalton Jul 1987 A
4689174 Lupke Aug 1987 A
4730616 Frisbie et al. Mar 1988 A
4769005 Ginsburg et al. Sep 1988 A
4774949 Fogarty Oct 1988 A
4896670 Crittenden Jan 1990 A
4900314 Quackenbush Feb 1990 A
4905667 Foerster et al. Mar 1990 A
4957508 Kaneko et al. Sep 1990 A
4983166 Yamawaki Jan 1991 A
4994071 MacGregor Feb 1991 A
5054501 Chuttani et al. Oct 1991 A
5122125 Deuss Jun 1992 A
5147317 Shank et al. Sep 1992 A
5156620 Pigott Oct 1992 A
5217440 Frassica Jun 1993 A
5219355 Parodi et al. Jun 1993 A
5244619 Burnham Sep 1993 A
5320605 Sahota Jun 1994 A
5337733 Bauerfeind et al. Aug 1994 A
5342387 Summers Aug 1994 A
5350395 Yock Sep 1994 A
5387235 Chuter Feb 1995 A
5404887 Prather Apr 1995 A
5417208 Winkler May 1995 A
5443497 Venbrux Aug 1995 A
5445624 Jimenez Aug 1995 A
5456712 Maginot Oct 1995 A
5458605 Klemm Oct 1995 A
5476471 Shifrin et al. Dec 1995 A
5487730 Marcadis et al. Jan 1996 A
5489271 Andersen Feb 1996 A
5496292 Burnham Mar 1996 A
5575771 Walinsky Nov 1996 A
5591228 Edoga Jan 1997 A
5599300 Weaver et al. Feb 1997 A
5607444 Lam Mar 1997 A
5609605 Marshall et al. Mar 1997 A
5609627 Goicoechea et al. Mar 1997 A
5613980 Chauhan Mar 1997 A
5617878 Taheri Apr 1997 A
5632762 Myler May 1997 A
5632763 Glastra May 1997 A
5632772 Alcime et al. May 1997 A
5636641 Fariabi Jun 1997 A
5639278 Dereume et al. Jun 1997 A
5669924 Shaknovich Sep 1997 A
5669932 Fishell et al. Sep 1997 A
5672153 Lax et al. Sep 1997 A
5676697 McDonald Oct 1997 A
5683450 Goicoechea et al. Nov 1997 A
5693086 Goicoechea et al. Dec 1997 A
5695516 Fischell et al. Dec 1997 A
5697971 Fischell et al. Dec 1997 A
5707348 Krogh Jan 1998 A
5709713 Evans et al. Jan 1998 A
5720735 Dorros Feb 1998 A
5749825 Fischell et al. May 1998 A
5749890 Shaknovich May 1998 A
5755734 Richter et al. May 1998 A
5755735 Richter et al. May 1998 A
5755770 Ravenscroft May 1998 A
5755771 Penn et al. May 1998 A
5755772 Evans et al. May 1998 A
5755773 Evans et al. May 1998 A
5755778 Kleshinski May 1998 A
5776101 Goy Jul 1998 A
5782906 Marshall et al. Jul 1998 A
5800508 Goicoechea et al. Sep 1998 A
5800520 Fogarty et al. Sep 1998 A
5824036 Lauterjung Oct 1998 A
5824040 Cox et al. Oct 1998 A
5827320 Richter et al. Oct 1998 A
5851464 Davila et al. Dec 1998 A
5853419 Imran Dec 1998 A
5855600 Alt Jan 1999 A
5868777 Lam Feb 1999 A
5893887 Jayaraman Apr 1999 A
5906640 Penn et al. May 1999 A
5916263 Goicoechea et al. Jun 1999 A
5921995 Kleshinski Jul 1999 A
5938696 Goicoechea et al. Aug 1999 A
5961490 Adams Oct 1999 A
5961548 Shmulewitz Oct 1999 A
5968089 Krajicek Oct 1999 A
5972017 Berg et al. Oct 1999 A
5984955 Wisselink Nov 1999 A
5993481 Marcade et al. Nov 1999 A
6013054 Jiun Yan Jan 2000 A
6013091 Ley et al. Jan 2000 A
6016810 Ravenscroft Jan 2000 A
6017324 Tu et al. Jan 2000 A
6017363 Jojeibane Jan 2000 A
6030414 Taheri Feb 2000 A
6033433 Ehr et al. Mar 2000 A
6033434 Borghi Mar 2000 A
6033435 Penn et al. Mar 2000 A
6039758 Quiachon et al. Mar 2000 A
6045557 White et al. Apr 2000 A
6048360 Khosravi et al. Apr 2000 A
6048361 Von Oepen Apr 2000 A
6051020 Goicoechea et al. Apr 2000 A
6056722 Jayaraman May 2000 A
6056775 Borghi et al. May 2000 A
6059824 Taheri May 2000 A
6068655 Seguin et al. May 2000 A
6071298 Lashinski et al. Jun 2000 A
6086611 Duffy et al. Jul 2000 A
6090133 Richter et al. Jul 2000 A
6093203 Uflacker Jul 2000 A
6096073 Webster et al. Aug 2000 A
6099497 Adams et al. Aug 2000 A
6099558 White Aug 2000 A
6099560 Penn et al. Aug 2000 A
6102938 Evans et al. Aug 2000 A
6113579 Eidenschink et al. Sep 2000 A
6117117 Mauch Sep 2000 A
6117156 Richter et al. Sep 2000 A
6129738 Lashinski et al. Oct 2000 A
6129754 Kanesaka et al. Oct 2000 A
6132459 Piplani et al. Oct 2000 A
6142973 Carleton et al. Nov 2000 A
6143002 Vietmeier Nov 2000 A
6159238 Killion et al. Dec 2000 A
6165195 Wilson et al. Dec 2000 A
6165213 Goccoechea et al. Dec 2000 A
6168621 Vrba Jan 2001 B1
6183509 Dibie Feb 2001 B1
6197046 Piplani et al. Mar 2001 B1
6197049 Shaolian et al. Mar 2001 B1
6203568 Lombardi et al. Mar 2001 B1
6210380 Mauch Apr 2001 B1
6210429 Vardi et al. Apr 2001 B1
6210431 Power Apr 2001 B1
6210433 Larre Apr 2001 B1
6217527 Selmon et al. Apr 2001 B1
6221080 Power Apr 2001 B1
6221090 Wilson Apr 2001 B1
6221098 Wilson et al. Apr 2001 B1
6231563 White et al. May 2001 B1
6231598 Berry et al. May 2001 B1
6238430 Klumb et al. May 2001 B1
6248122 Klumb et al. Jun 2001 B1
6251133 Richter et al. Jun 2001 B1
6254593 Wilson Jul 2001 B1
6258073 Mauch Jul 2001 B1
6258115 Dubrul Jul 2001 B1
6258116 Hojeibane Jul 2001 B1
6261273 Ruiz Jul 2001 B1
6261305 Marotta et al. Jul 2001 B1
6261316 Shaolian et al. Jul 2001 B1
6264662 Lauterjung Jul 2001 B1
6264686 Rieu et al. Jul 2001 B1
6273909 Kugler et al. Aug 2001 B1
6283991 Cox et al. Sep 2001 B1
6287277 Yan Sep 2001 B1
6290673 Shanley Sep 2001 B1
6293968 Taheri Sep 2001 B1
6302906 Goicoechea et al. Oct 2001 B1
6302908 Parodi Oct 2001 B1
6306164 Kujawski Oct 2001 B1
6312461 Unsworth et al. Nov 2001 B1
6319278 Quinn et al. Nov 2001 B1
6322587 Quiachon et al. Nov 2001 B1
6325819 Pavcnik et al. Dec 2001 B1
6325822 Chouinard et al. Dec 2001 B1
6325826 Vardi et al. Dec 2001 B1
6334864 Amplatz et al. Jan 2002 B1
6334870 Ehr Jan 2002 B1
6346089 Dibie Feb 2002 B1
6355060 Lenker et al. Mar 2002 B1
6361544 Wilson et al. Mar 2002 B1
6361555 Wilson Mar 2002 B1
6383213 Wilson et al. May 2002 B2
6387120 Wilson et al. May 2002 B2
6395018 Castaneda May 2002 B1
6436104 Hojeibane Aug 2002 B2
6436134 Richter et al. Aug 2002 B2
6468301 Amplatz et al. Oct 2002 B1
6508836 Wilson et al. Jan 2003 B2
6517558 Gittings et al. Feb 2003 B2
6520988 Colombo et al. Feb 2003 B1
6537284 Inoue Mar 2003 B1
6540779 Richter et al. Apr 2003 B2
6579309 Loos Jun 2003 B1
6579312 Wilson et al. Jun 2003 B2
6582394 Reiss Jun 2003 B1
6596020 Vardi et al. Jul 2003 B2
6599315 Wilson Jul 2003 B2
6599316 Vardi et al. Jul 2003 B2
6645242 Quinn Nov 2003 B1
6689156 Davidson et al. Feb 2004 B1
6692483 Vardi et al. Feb 2004 B2
6695877 Brucker et al. Feb 2004 B2
6706062 Vardi et al. Mar 2004 B2
6749628 Callol et al. Jun 2004 B1
6776793 Brown et al. Aug 2004 B2
6811566 Penn et al. Nov 2004 B1
6835203 Vardi Dec 2004 B1
6858038 Heuser Feb 2005 B2
6884258 Vardi et al. Apr 2005 B2
6896699 Wilson et al. May 2005 B2
6932837 Amplatz et al. Aug 2005 B2
6955687 Richter et al. Oct 2005 B2
6955688 Wilson et al. Oct 2005 B2
6962602 Vardi et al. Nov 2005 B2
7018400 Lashinski et al. Mar 2006 B2
7056323 Mareiro et al. Jun 2006 B2
7060091 Killion et al. Jun 2006 B2
7341598 Davidson et al. Mar 2008 B2
20010002443 Parodi May 2001 A1
20010002927 Detampel Jun 2001 A1
20010002943 Nagayama et al. Jun 2001 A1
20010003161 Vardi et al. Jun 2001 A1
20010004705 Killion et al. Jun 2001 A1
20010004706 Hojeibane Jun 2001 A1
20010004707 Dereume et al. Jun 2001 A1
20010004823 Cronin et al. Jun 2001 A1
20010007954 Shaolian et al. Jul 2001 A1
20010012927 Mauch Aug 2001 A1
20010016766 Vardi et al. Aug 2001 A1
20010016767 Wilson et al. Aug 2001 A1
20010016768 Wilson et al. Aug 2001 A1
20010020173 Klumb et al. Sep 2001 A1
20010020184 Dehdashtian et al. Sep 2001 A1
20010025195 Shaolian et al. Sep 2001 A1
20010027291 Shanley Oct 2001 A1
20010027338 Greenberg Oct 2001 A1
20010029396 Wilson et al. Oct 2001 A1
20010037116 Wilson et al. Nov 2001 A1
20010037138 Wilson et al. Nov 2001 A1
20010039448 Dibie Nov 2001 A1
20010047199 Wijay Nov 2001 A1
20010049552 Richter et al. Dec 2001 A1
20010056297 Hojeibane Dec 2001 A1
20020013618 Marotta et al. Jan 2002 A1
20020013619 Shanley Jan 2002 A1
20020022874 Wilson Feb 2002 A1
20020026232 Marotta et al. Feb 2002 A1
20020035392 Wilson Mar 2002 A1
20020042650 Vardi et al. Apr 2002 A1
20020052648 McGuckin, Jr. et al. May 2002 A1
20020072790 McGuckin, Jr. et al. Jun 2002 A1
20020111675 Wilson Aug 2002 A1
20020123791 Harrison Sep 2002 A1
20020156516 Vardi et al. Oct 2002 A1
20020156517 Perouse Oct 2002 A1
20020165604 Shanley Nov 2002 A1
20020173835 Bourang et al. Nov 2002 A1
20020173840 Brucker et al. Nov 2002 A1
20020183763 Callol et al. Dec 2002 A1
20020193872 Trout, III et al. Dec 2002 A1
20020193873 Brucker Dec 2002 A1
20030009209 Hojeibane Jan 2003 A1
20030028233 Vardi et al. Feb 2003 A1
20030050688 Fischell et al. Mar 2003 A1
20030055378 Wang et al. Mar 2003 A1
20030055483 Gumm Mar 2003 A1
20030074047 Richter Apr 2003 A1
20030093109 Mauch May 2003 A1
20030097169 Brucker May 2003 A1
20030114912 Sequin et al. Jun 2003 A1
20030125791 Sequin et al. Jul 2003 A1
20030125802 Callol et al. Jul 2003 A1
20030135259 Simso Jul 2003 A1
20030181923 Vardi Sep 2003 A1
20030195606 Davidson et al. Oct 2003 A1
20040006381 Sequin et al. Jan 2004 A1
20040015227 Vardi et al. Jan 2004 A1
20040044396 Clerc et al. Mar 2004 A1
20040059406 Cully et al. Mar 2004 A1
20040088007 Eidenschink May 2004 A1
20040117003 Ouriel et al. Jun 2004 A1
20040133268 Davidson et al. Jul 2004 A1
20040138732 Suhr et al. Jul 2004 A1
20040138737 Davidson et al. Jul 2004 A1
20040148006 Davidson et al. Jul 2004 A1
20040172121 Eidenschink et al. Sep 2004 A1
20040186560 Alt Sep 2004 A1
20040225345 Fischell et al. Nov 2004 A1
20040267352 Davidson Dec 2004 A1
20050004656 Das Jan 2005 A1
20050010278 Vardi et al. Jan 2005 A1
20050015108 Williams et al. Jan 2005 A1
20050015135 Shanley Jan 2005 A1
20050060027 Khenansho et al. Mar 2005 A1
20050096726 Sequin et al. May 2005 A1
20050102021 Osborne May 2005 A1
20050102023 Yadin et al. May 2005 A1
20050113909 Shannon et al. May 2005 A1
20050119731 Brucker et al. Jun 2005 A1
20050125051 Eidenschink et al. Jun 2005 A1
20050125076 Ginn Jun 2005 A1
20050131526 Wong Jun 2005 A1
20050149161 Eidenschink et al. Jul 2005 A1
20050154442 Eidenschink et al. Jul 2005 A1
20050154444 Quadri et al. Jul 2005 A1
20050183259 Eidenschink et al. Aug 2005 A1
20050209673 Shaked Sep 2005 A1
20050228483 Kaplan Oct 2005 A1
20060036315 Yadin et al. Feb 2006 A1
20060041303 Israel Feb 2006 A1
20060079956 Eigler et al. Apr 2006 A1
20060173528 Feld et al. Aug 2006 A1
20070073376 Krolik et al. Mar 2007 A1
20070208411 Meyer et al. Sep 2007 A1
20070276464 Valencia et al. Nov 2007 A1
20080065197 Meyer et al. Mar 2008 A1
20080086200 Macha Apr 2008 A1
Foreign Referenced Citations (124)
Number Date Country
2220864 Jul 1999 CA
9014845 Feb 1991 DE
29701883 Mar 1997 DE
29701758 May 1997 DE
0479730 Oct 1991 EP
0686379 Dec 1995 EP
0751752 Jan 1997 EP
0783873 Jul 1997 EP
0804907 Nov 1997 EP
0479557 Jul 1998 EP
0876805 Nov 1998 EP
0647148 Dec 1998 EP
0880949 Dec 1998 EP
0891751 Jan 1999 EP
0895759 Feb 1999 EP
0897700 Feb 1999 EP
0904745 Mar 1999 EP
0937442 Aug 1999 EP
0347023 Dec 1999 EP
1031328 Aug 2000 EP
1031329 Aug 2000 EP
1031330 Aug 2000 EP
0883384 Dec 2000 EP
0862392 Aug 2001 EP
0808140 Dec 2001 EP
0884028 Feb 2002 EP
1190685 Mar 2002 EP
0684022 Feb 2004 EP
1157674 Jul 2005 EP
1070513 Jun 2006 EP
2678508 Jul 1991 FR
2740346 Oct 1995 FR
2756173 Nov 1996 FR
2760351 Mar 1997 FR
2337002 May 1998 GB
8806026 Aug 1988 WO
9219308 Nov 1992 WO
9510442 Apr 1995 WO
9521592 Aug 1995 WO
9629955 Oct 1996 WO
9634580 Nov 1996 WO
9641592 Dec 1996 WO
9707752 Mar 1997 WO
9715346 May 1997 WO
9716217 May 1997 WO
9726936 Jul 1997 WO
9741803 Nov 1997 WO
9745073 Dec 1997 WO
9746174 Dec 1997 WO
9819628 May 1998 WO
9836709 Aug 1998 WO
9837833 Sep 1998 WO
9847446 Oct 1998 WO
9847447 Oct 1998 WO
9848879 Nov 1998 WO
9853759 Dec 1998 WO
9903426 Jan 1999 WO
9903462 Jan 1999 WO
9904726 Feb 1999 WO
9913808 Mar 1999 WO
9915103 Apr 1999 WO
9915108 Apr 1999 WO
9915109 Apr 1999 WO
9924104 May 1999 WO
9934749 Jul 1999 WO
9936002 Jul 1999 WO
9936015 Jul 1999 WO
9944539 Sep 1999 WO
9956661 Nov 1999 WO
9965419 Dec 1999 WO
0007523 Feb 2000 WO
0010485 Mar 2000 WO
0010489 Mar 2000 WO
0013613 Mar 2000 WO
0016719 Mar 2000 WO
0027307 May 2000 WO
0027463 May 2000 WO
0028922 May 2000 WO
0032266 Jun 2000 WO
0044307 Aug 2000 WO
0044309 Aug 2000 WO
0047134 Aug 2000 WO
0048531 Aug 2000 WO
0049951 Aug 2000 WO
0051523 Sep 2000 WO
0057813 Oct 2000 WO
0071054 Nov 2000 WO
0067673 Nov 2000 WO
0071055 Nov 2000 WO
0074595 Dec 2000 WO
0121095 Mar 2001 WO
0121109 Mar 2001 WO
0121244 May 2001 WO
0130433 May 2001 WO
0135715 May 2001 WO
0135863 May 2001 WO
0139697 Jun 2001 WO
0139699 Jun 2001 WO
0141677 Jun 2001 WO
0143665 Jun 2001 WO
0143809 Jun 2001 WO
0145594 Jun 2001 WO
0145785 Jun 2001 WO
0149342 Jul 2001 WO
0154621 Aug 2001 WO
0154622 Aug 2001 WO
0158385 Aug 2001 WO
0160284 Aug 2001 WO
0170294 Sep 2001 WO
0170299 Sep 2001 WO
0174273 Oct 2001 WO
0189409 Nov 2001 WO
0200138 Jan 2002 WO
02053066 Jul 2002 WO
02068012 Sep 2002 WO
03007842 Jan 2003 WO
03055414 Jul 2003 WO
03063924 Aug 2003 WO
2004026174 Apr 2004 WO
2004026180 Apr 2004 WO
2004026180 Apr 2004 WO
2005009295 Feb 2005 WO
2005014077 Feb 2005 WO
2006028925 Mar 2006 WO
Related Publications (1)
Number Date Country
20070135903 A1 Jun 2007 US